Treatment options for relapsed small-cell lung cancer

Hatem A. Azim, Apar Kishor P Ganti

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Small-cell lung cancer is a chemo-sensitive disease with a response rate ranging from 70 to 90% for first-line treatment; however, relapses are very common and as a result long-term survival is poor. Chemotherapy has demonstrated a benefit over the best supportive care, even in patients who have relapsed after initial treatment with a platinum-based regimen. Agents currently being used in salvage therapy include topotecan, cyclophosphamide, doxorubicin and vincristine regimen. In the last 5 years, several drugs have shown promise in initial evaluation; however, randomized phase III trials would be needed to answer this question. Our understanding of the biology of small-cell lung cancer has improved dramatically over the past few years and this has translated into the developments of new therapeutic targets for this disease. Agents affecting several targets, including bcl-2, matrix metalloproteinases, epidermal growth factors and angiogenesis, are being studied currently and have the potential to change the treatment paradigms of this otherwise fatal malignancy. This review focuses on the various current and future options, including cytoxic and targeted agents, for salvage therapy in patients with this disease.

Original languageEnglish (US)
Pages (from-to)255-261
Number of pages7
JournalAnti-Cancer Drugs
Volume18
Issue number3
DOIs
StatePublished - Mar 1 2007

Fingerprint

Small Cell Lung Carcinoma
Salvage Therapy
Topotecan
Matrix Metalloproteinase 2
Vincristine
Therapeutics
Platinum
Doxorubicin
Cyclophosphamide
Recurrence
Drug Therapy
Survival
Pharmaceutical Preparations
Neoplasms

Keywords

  • Second-line therapy
  • Small-cell lung cancer
  • Targeted therapies
  • Topoisomerase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Cite this

Treatment options for relapsed small-cell lung cancer. / Azim, Hatem A.; Ganti, Apar Kishor P.

In: Anti-Cancer Drugs, Vol. 18, No. 3, 01.03.2007, p. 255-261.

Research output: Contribution to journalReview article

@article{83313d3f2ed743cb809578fef7ed0f79,
title = "Treatment options for relapsed small-cell lung cancer",
abstract = "Small-cell lung cancer is a chemo-sensitive disease with a response rate ranging from 70 to 90{\%} for first-line treatment; however, relapses are very common and as a result long-term survival is poor. Chemotherapy has demonstrated a benefit over the best supportive care, even in patients who have relapsed after initial treatment with a platinum-based regimen. Agents currently being used in salvage therapy include topotecan, cyclophosphamide, doxorubicin and vincristine regimen. In the last 5 years, several drugs have shown promise in initial evaluation; however, randomized phase III trials would be needed to answer this question. Our understanding of the biology of small-cell lung cancer has improved dramatically over the past few years and this has translated into the developments of new therapeutic targets for this disease. Agents affecting several targets, including bcl-2, matrix metalloproteinases, epidermal growth factors and angiogenesis, are being studied currently and have the potential to change the treatment paradigms of this otherwise fatal malignancy. This review focuses on the various current and future options, including cytoxic and targeted agents, for salvage therapy in patients with this disease.",
keywords = "Second-line therapy, Small-cell lung cancer, Targeted therapies, Topoisomerase inhibitors",
author = "Azim, {Hatem A.} and Ganti, {Apar Kishor P}",
year = "2007",
month = "3",
day = "1",
doi = "10.1097/CAD.0b013e328011a547",
language = "English (US)",
volume = "18",
pages = "255--261",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Treatment options for relapsed small-cell lung cancer

AU - Azim, Hatem A.

AU - Ganti, Apar Kishor P

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Small-cell lung cancer is a chemo-sensitive disease with a response rate ranging from 70 to 90% for first-line treatment; however, relapses are very common and as a result long-term survival is poor. Chemotherapy has demonstrated a benefit over the best supportive care, even in patients who have relapsed after initial treatment with a platinum-based regimen. Agents currently being used in salvage therapy include topotecan, cyclophosphamide, doxorubicin and vincristine regimen. In the last 5 years, several drugs have shown promise in initial evaluation; however, randomized phase III trials would be needed to answer this question. Our understanding of the biology of small-cell lung cancer has improved dramatically over the past few years and this has translated into the developments of new therapeutic targets for this disease. Agents affecting several targets, including bcl-2, matrix metalloproteinases, epidermal growth factors and angiogenesis, are being studied currently and have the potential to change the treatment paradigms of this otherwise fatal malignancy. This review focuses on the various current and future options, including cytoxic and targeted agents, for salvage therapy in patients with this disease.

AB - Small-cell lung cancer is a chemo-sensitive disease with a response rate ranging from 70 to 90% for first-line treatment; however, relapses are very common and as a result long-term survival is poor. Chemotherapy has demonstrated a benefit over the best supportive care, even in patients who have relapsed after initial treatment with a platinum-based regimen. Agents currently being used in salvage therapy include topotecan, cyclophosphamide, doxorubicin and vincristine regimen. In the last 5 years, several drugs have shown promise in initial evaluation; however, randomized phase III trials would be needed to answer this question. Our understanding of the biology of small-cell lung cancer has improved dramatically over the past few years and this has translated into the developments of new therapeutic targets for this disease. Agents affecting several targets, including bcl-2, matrix metalloproteinases, epidermal growth factors and angiogenesis, are being studied currently and have the potential to change the treatment paradigms of this otherwise fatal malignancy. This review focuses on the various current and future options, including cytoxic and targeted agents, for salvage therapy in patients with this disease.

KW - Second-line therapy

KW - Small-cell lung cancer

KW - Targeted therapies

KW - Topoisomerase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=33846661914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846661914&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e328011a547

DO - 10.1097/CAD.0b013e328011a547

M3 - Review article

VL - 18

SP - 255

EP - 261

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 3

ER -